Global Clinical Oncology Next Generation Sequencing Market Size study & Forecast, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing) by Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), by A

Global Clinical Oncology Next Generation Sequencing Market Size study & Forecast, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing) by Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), by Application (Screening, Companion Diagnostics, Others), by End Use (Hospitals, Clinics, Laboratories) and Regional Analysis, 2023-2030

Global Clinical Oncology Next Generation Sequencing Market is valued at approximately USD 370.0 million in 2022 and is anticipated to grow with a healthy growth rate of more than 15.70% over the forecast period 2023-2030. Clinical Oncology Next Generation Sequencing (NGS) refers to the application of advanced genomic sequencing technologies in the field of oncology, specifically for diagnosing and managing cancer. NGS is a high-throughput sequencing technique that enables the simultaneous analysis of multiple genes or genomic regions, providing comprehensive genetic information about a tumor. The Clinical Oncology Next Generation Sequencing market is expanding because of factors such as rising prevelance of cancer disorders, rising investment in research & development activities to invent solutions and growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer.

The increasing prevalence of cancer has spurred a rapid expansion of cancer research initiatives worldwide. NGS technology has become a cornerstone in cancer genomics research, facilitating large-scale genomic studies and collaborative efforts to unravel the complex genetic landscape of various cancer types. These research efforts contribute to the development of novel therapies, identification of new targets, and improved understanding of cancer biology. according to estimates from the International Agency for Research on Cancer (IARC), in year 2021 there were around 1.9 million new cancer cases across the world, and it is projected to increase at 27.5 million new cases by year 2040, worldwide. Moreover, key market players in the market are developing new platforms for the clinical uses of NGS in precision oncology resulting in market growth. For instance, a major company in the industry, In August 2022, Thermo Fisher Scientific launched NGS Analysis and Test Software CE-IVD (IVDD) in order to make precision oncology biomarker testing more widely available. Healthcare professionals can swiftly assess the outcomes of genomic tests thanks to this software. The software evaluates the variation data in light of pertinent data, such as supported recommendations, treatments, clinical studies, and peer-reviewed literature. Such developments in NGS clinical applications may increase consumer demand. In addition, technological advancements in next-generation sequencing (NGS) and growing adoption of companion diagnostics and personalized medicine is creating a lucrative opportunity in the market. However, the lack of computational efficiency for data management stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Clinical Oncology Next Generation Sequencing Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, rising research and development for precision oncology, rising investment in development of product, and rising government support to the healthcare industry. Asia Pacific is projected to have significant growth in the market space owing to factors such as rising prevelance of cancer, rising healthcare expenditure and rising government investment in oncology drug development activities.

Major market player included in this report are:
Illumina, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Agilent Technologies, Inc.
Myriad Genetics, Inc.
Beijing Genomics Institute (BGI)
Perkin Elmer, Inc.
Oxford Nanopore Technologies
Paradigm Diagnostics, Inc.
PerkinElmer, Inc.

Recent Developments in the Market:
In February 2023, F. Hoffmann-La Roche Ltd. and Janssen Biotech Inc. (Janssen) expanded their collaboration in order to create companion diagnostics for targeted treatments and to include a wide spectrum of companion diagnostics, including tissue- and blood-based biomarkers, digital pathology, and sequencing pathology.
In June 2023, Illumina Inc., a producer of DNA sequencing and array-based technologies, developed the artificial intelligence system PrimateAI-3D, which had previously unheard-of accuracy in foretelling disease-causing genetic defects in individuals.

Global Clinical Oncology Next Generation Sequencing Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Technology, Workflow, Type, End-use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing

By Workflow:
NGS Pre-Sequencing
NGS Sequencing
NGS Data Analysis
By Application:
Screening
Companion Diagnostics
Others
By End-use:
Hospitals
Clinics
Laboratories

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Illumina, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Agilent Technologies, Inc.
Myriad Genetics, Inc.
Beijing Genomics Institute (BGI)
Perkin Elmer, Inc.
Oxford Nanopore Technologies
Paradigm Diagnostics, Inc.
PerkinElmer, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.